China NMPA Drug Inspection - Fujian Mengshi Pharmaceutical Co., Ltd. - jellyfish

The Gansu Provincial Drug Administration, in its Announcement No. 28 of 2019 published on August 7, 2019, reported findings from a drug quality inspection conducted by the Lanzhou Municipal Food and Drug Inspection Institute. The inspection identified 10 batches of drugs from nine manufacturers as substandard. Companies implicated include Jiangxi Guodu Traditional Chinese Medicine Pieces Co., Ltd., Hebei Renxin Pharmaceutical Co., Ltd., and Gansu Guocao Pharmaceutical Co., Ltd. The main violations centered on failures to comply with quality standards outlined in the Chinese Pharmacopoeia 2015 Edition, Part I. Specific issues ranged from non-compliance in product properties, such as appearance and physical characteristics, to excessive total ash content and unacceptable levels of sulfur dioxide residue, indicative of potential impurities or improper processing. Regulatory authorities have taken immediate control measures, including sealing and seizing the affected products. Investigations against the non-compliant entities have been initiated or are in progress, with results expected to be publicized within three months. Additionally, municipal and prefectural market supervision bureaus are tasked with strengthening oversight, ensuring companies investigate root causes, implement rectification measures, and effectively mitigate public health risks.